- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
Patent holdings for IPC class C07D 265/30
Total number of patents in this class: 901
10-year publication summary
|
54
|
47
|
54
|
64
|
56
|
49
|
64
|
65
|
62
|
37
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10849 |
22 |
| Supernus Pharmaceuticals, Inc. | 137 |
20 |
| 3m Innovative Properties Company | 17833 |
17 |
| F. Hoffmann-La Roche AG | 7925 |
15 |
| The Regents of the University of California | 19918 |
14 |
| Corsair Pharma, Inc. | 37 |
13 |
| Global Blood Therapeutics, Inc. | 183 |
13 |
| Bristol-myers Squibb Company | 4898 |
12 |
| Boehringer Ingelheim International GmbH | 4650 |
12 |
| Hoffmann-La Roche Inc. | 3418 |
11 |
| BASF SE | 20933 |
11 |
| Allergan, Inc. | 2349 |
10 |
| Merck Sharp & Dohme LLC | 3748 |
9 |
| Janssen Pharmaceutica N.V. | 3392 |
8 |
| Astellas Pharma Inc. | 1088 |
8 |
| Glaxosmithkline LLC | 537 |
7 |
| Duke University | 3066 |
7 |
| Adverio Pharma GmbH | 45 |
7 |
| Korea University Research and Business Foundation | 2975 |
7 |
| Lundbeck Pharmaceuticals Italy S.p.A. | 25 |
7 |
| Other owners | 671 |